经皮心肌内室间隔射频消融术治疗肥厚型梗阻性心肌病
本研究纳入15例肥厚型梗阻性心肌病患者,评估超声引导下经皮心肌内室间隔射频消融术(PIMSRA)的安全性和有效性。6个月随访显示,静息和负荷状态下左心室流出道(LVOT)压差及室间隔厚度均显著降低,NYHA心功能分级、总运动时间和pro B型利钠肽水平均改善,且无患者发生束支传导阻滞或完全性心脏传导阻滞。
要点
- PIMSRA可显著降低HOCM患者静息和负荷LVOT压差及室间隔厚度。
- PIMSRA改善NYHA分级、运动耐量和pro BNP水平,且无严重传导阻滞。
- PIMSRA是严重症状性HOCM安全有效的微创治疗选择。
核心结论
- PIMSRA是严重症状性肥厚型梗阻性心肌病的安全有效治疗方法,可持久降低LVOT压差、改善运动能力和心功能。
研究设计与样本
- 本研究纳入15例肥厚型梗阻性心肌病患者,接受超声引导下经皮心肌内室间隔射频消融术,随访6个月,进行心电图、影像学和血液生化检查。
主要发现
- 6个月随访时,静息LVOT压差从88.00 [66.00] mm Hg降至11.00 [6.00] mm Hg(p=0.001),负荷LVOT压差从117.00 [81.00] mm Hg降至25.00 [20.00] mm Hg(p=0.005)。
- 前室间隔厚度从25.00 [21.00] mm降至14.00 [12.00] mm(p=0.001),后室间隔厚度从24.00 [21.00] mm降至14.00 [11.50] mm(p=0.001)。
- NYHA分级从3.00 [2.00]改善至1.00 [1.00](p<0.001),总运动时间从6.00 [5.50] min延长至9.00 [8.00] min(p=0.007),pro B型利钠肽从924.00 [370.45] pg/ml降至137.45 [75.73] pg/ml(p=0.028)。
- 无患者发生束支传导阻滞或完全性心脏传导阻滞。
临床怎么用
- 对于严重症状性肥厚型梗阻性心肌病患者,PIMSRA可作为微创治疗选择,术后6个月可观察到LVOT压差和室间隔厚度显著降低及心功能改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with disabling symptoms caused by hypertrophic obstructive cardiomyopathy (HOCM), echocardiography-guided percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) could be a less invasive treatment option. OBJECTIVES: This study aimed to investigate the safety and efficacy of the PIMSRA for left ventricular outflow tract (LVOT) gradient reduction in HOCM. METHODS: The study enrolled 15 patients with HOCM. These patients underwent electrocardiography, imaging, and blood biochemistry examination over 6 months of follow-up. RESULTS: At 6 months of follow-up, patients showed significant reductions in peak LVOT gradients (resting gradient: from 88.00 [66.00] mm Hg to 11.00 [6.00] mm Hg; p = 0.001; stress-induced gradient: from 117.00 [81.00] mm Hg to 25.00 [20.00] mm Hg; p = 0.005) and interventricular septum (IVS) thickness (anterior IVS: from 25.00 [21.00] mm to 14.00 [12.00] mm; p = 0.001; posterior IVS: from 24.00 [21.00] mm to 14.00 [11.50] mm; p = 0.001). The reductions in IVS thickness and LVOT gradients were associated with improvement in New York Heart Association functional classification (from 3.00 [2.00] to 1.00 [1.00]; p < 0.001), total exercise time (from 6.00 [5.50] min to 9.00 [8.00] min; p = 0.007), and pro B-type natriuretic peptide levels (from 924.00 [370.45] pg/ml to 137.45 [75.73] pg/ml; p = 0.028). No patient had bundle branch block or complete heart block. CONCLUSIONS: PIMSRA is a safe and effective treatment approach for severe, symptomatic HOCM and results in sustained improvement in exercise capacity, persistent reduction in LVOT gradient, and sustained improvement in cardiac function.
引用
- Liu L, Li J, Zuo L, et al. Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol. 2018. PMID: 30309466. doi:10.1016/j.jacc.2018.07.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。